Cargando…
Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk
The use of atorvastatin is rapidly increasing among statins since the introduction of generics. However, only limited data are available on its current use and the effectiveness outside of randomised trials. The aim of the study was to assess low-density lipoprotein (LDL-C) levels in ambulatory pati...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989032/ https://www.ncbi.nlm.nih.gov/pubmed/27120330 http://dx.doi.org/10.1007/s00392-016-0991-z |
_version_ | 1782448502765256704 |
---|---|
author | Laufs, Ulrich Karmann, Barbara Pittrow, David |
author_facet | Laufs, Ulrich Karmann, Barbara Pittrow, David |
author_sort | Laufs, Ulrich |
collection | PubMed |
description | The use of atorvastatin is rapidly increasing among statins since the introduction of generics. However, only limited data are available on its current use and the effectiveness outside of randomised trials. The aim of the study was to assess low-density lipoprotein (LDL-C) levels in ambulatory patients at very high cardiovascular risk on atorvastatin therapy in physician’s offices. A total of 2625 high-risk patients on atorvastatin were included into this cross-sectional study by 539 office-based physicians between June and December 2014. 47.0 % of the patients had documented coronary heart disease (CHD), 25.1 % type 2 diabetes mellitus (DM), and 27.9 % CHD plus concomitant DM. The mean age was 66.1 ± 10.8 years, 62.1 % were male. Atorvastatin at the dose of 10, 20, 40 and 80 mg/day was administered in 15.6, 45.7, 33.9, and 4.8 % of the patients, respectively. The treatment duration was 92.6 ± 109.6 weeks. The mean atorvastatin dose at therapy start was 24.8 ± 15.2 mg/day and at time of documentation 27.9 ± 15.8 mg/day. Low-density lipoprotein cholesterol (LDL-C) <70 mg/dL was achieved by 10.5 % of the total cohort (7.5 % in DM, 9.3 % in CHD, and 15.2 % in CHD + DM). In contrast, according to physicians’ subjective assessment, 62.7 % of patients (with small differences between groups) had reached their individual LDL-C target. In summary, higher doses of atorvastatin are not frequently used in clinical practice. The LDL-C target level <70 mg/dL as recommended by current guidelines is achieved only in a minority of atorvastatin treated patients at very high cardiovascular risk. |
format | Online Article Text |
id | pubmed-4989032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-49890322016-09-01 Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk Laufs, Ulrich Karmann, Barbara Pittrow, David Clin Res Cardiol Original Paper The use of atorvastatin is rapidly increasing among statins since the introduction of generics. However, only limited data are available on its current use and the effectiveness outside of randomised trials. The aim of the study was to assess low-density lipoprotein (LDL-C) levels in ambulatory patients at very high cardiovascular risk on atorvastatin therapy in physician’s offices. A total of 2625 high-risk patients on atorvastatin were included into this cross-sectional study by 539 office-based physicians between June and December 2014. 47.0 % of the patients had documented coronary heart disease (CHD), 25.1 % type 2 diabetes mellitus (DM), and 27.9 % CHD plus concomitant DM. The mean age was 66.1 ± 10.8 years, 62.1 % were male. Atorvastatin at the dose of 10, 20, 40 and 80 mg/day was administered in 15.6, 45.7, 33.9, and 4.8 % of the patients, respectively. The treatment duration was 92.6 ± 109.6 weeks. The mean atorvastatin dose at therapy start was 24.8 ± 15.2 mg/day and at time of documentation 27.9 ± 15.8 mg/day. Low-density lipoprotein cholesterol (LDL-C) <70 mg/dL was achieved by 10.5 % of the total cohort (7.5 % in DM, 9.3 % in CHD, and 15.2 % in CHD + DM). In contrast, according to physicians’ subjective assessment, 62.7 % of patients (with small differences between groups) had reached their individual LDL-C target. In summary, higher doses of atorvastatin are not frequently used in clinical practice. The LDL-C target level <70 mg/dL as recommended by current guidelines is achieved only in a minority of atorvastatin treated patients at very high cardiovascular risk. Springer Berlin Heidelberg 2016-04-27 2016 /pmc/articles/PMC4989032/ /pubmed/27120330 http://dx.doi.org/10.1007/s00392-016-0991-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Laufs, Ulrich Karmann, Barbara Pittrow, David Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk |
title | Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk |
title_full | Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk |
title_fullStr | Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk |
title_full_unstemmed | Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk |
title_short | Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk |
title_sort | atorvastatin treatment and ldl cholesterol target attainment in patients at very high cardiovascular risk |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989032/ https://www.ncbi.nlm.nih.gov/pubmed/27120330 http://dx.doi.org/10.1007/s00392-016-0991-z |
work_keys_str_mv | AT laufsulrich atorvastatintreatmentandldlcholesteroltargetattainmentinpatientsatveryhighcardiovascularrisk AT karmannbarbara atorvastatintreatmentandldlcholesteroltargetattainmentinpatientsatveryhighcardiovascularrisk AT pittrowdavid atorvastatintreatmentandldlcholesteroltargetattainmentinpatientsatveryhighcardiovascularrisk |